Overview


According to FutureWise analysis, the market for Advanced Glycation End Products is expected to grow at a CAGR of 5.60% over the forecast period of 2023-2031.

Advanced Glycation End Products (AGEs) are detrimental compounds that emerge when sugars interact with proteins or fats in the bloodstream, a process termed glycation. This reaction occurs naturally due to aging but is significantly accelerated when certain foods cook at high temperatures. Additionally, AGEs can be formed within the body by consuming foods rich in these compounds, particularly those exposed to high heat during preparation methods like grilling, frying, or toasting. Diet constitutes the most significant source of AGEs, and while the body possesses mechanisms involving antioxidants and enzymes to neutralize these compounds, an excessive intake or spontaneous production can overwhelm the elimination processes, leading to AGE accumulation. 

Although minimal AGE levels are generally considered benign, heightened concentrations have been associated with triggering oxidative stress and inflammation, which are involved in developing various health issues. Numerous diseases, including diabetes, heart disease, kidney failure, Alzheimer’s, and premature aging, have been linked to elevated AGE levels. Moreover, individuals with high blood sugar levels, such as those with diabetes, face an increased risk of producing excessive AGEs, further amplifying the potential for harmful accumulation within the body. Recognizing the pivotal role of AGEs in these health outcomes underscores the importance of understanding their origins and effects, thereby guiding efforts to regulate their intake and reduce associated risks.

FutureWise Market Research has published a report that provides an insightful analysis of Advanced Glycation End Products Market trends that are affecting the overall market growth. This report will provide a detailed analysis of market share, regional insights, and competitor analysis that includes stature of key manufacturers operational in this industry. By the end of the forecast period FutureWise research analysts’ projects that Advanced Glycation End Products Market will experience a significant growth.

According to the analysis done, this report will help understand the information referring to the total valuation held by this industry. Additionally, this report will help in understanding the growth opportunities held by various segments of this market, further assist in making better strategic and expansion decisions by key stakeholders of an organization.

  • Merck KGaA
  • Diagnoptics Technologies B.V.
  • Cell Biolabs, Inc.
  • Shanghai Korain Biotech Co., Ltd.
  • Scent-Sations, Inc.
  • Z.I. de la Nau.
  • Koken Co., Ltd.
  • Rodan & Fields Allergan PlcQ
  • CHF Solutions
  • Loreal S.A.
  • Alma Laser
  • PhotoMedex Inc.
  • NuFace
  • Beiersdorf AG
  • Takeda
  • Bayer
  • Shiseido Company
  • Ostium Cosmetics
  • Estee Lauder Companies

(Note: The list of the major players will be updated with the latest market scenario and trends)

The trajectory of the Advanced Glycation End Products (AGEs) Market is shaped by a complex interplay of propelling factors and constraining elements. On the affirmative side, the rising prevalence of chronic conditions, most notably diabetes, accentuates the demand for interventions and diagnostics directed at AGEs. The expanding elderly demographic further underscores the persistent requirement for treatments addressing complications linked to AGEs. Augmented awareness among healthcare practitioners and patients regarding AGEs' involvement in various diseases impels market momentum. Strides in analytical techniques and imaging technologies bolster the detection capabilities of AGEs, kindling research endeavours. Collaborative initiatives between research institutions and pharmaceutical enterprises fuel innovation, broadening the scope of the AGEs market.

Yet, the market confronts substantial limitations that temper its growth. The intricacy of AGEs-associated ailments, often characterized by intricate physiological pathways, poses hurdles for crafting precise therapeutic approaches. Stringent regulatory frameworks and protracted drug approval procedures can impede the timely introduction of novel AGE treatments. Economic considerations and pricing pressures might curtail patient accessibility to potentially costly AGE interventions. The interdisciplinary nature of AGE research necessitates harmonious collaboration among experts from diverse fields, which might need clarification from communication barriers and conflicting priorities. Moreover, decoding AGE data and its correlation with disease progression can be intricate, potentially impacting clinical decisions. As these dynamic drivers and restraints intertwine, embracing a comprehensive approach that harmonizes innovation, regulatory adherence, interdisciplinary collaboration, and equitable patient reach emerges as a pivotal navigational strategy to shape the path of the AGEs market.

By Type

  • Non-fluorescent AGEs
    • Carboxymethyl-lysine (CML)
    • Carboxyethyl-lysine (CEL)
    • Pyrraline
  • Fluorescent AGEs
    • Pentosidine
    • Methylglyoxal-lysine dimer (MOLD)

By Application

  • Diabetic Complications
  • Cancer
  • Bone Diseases
  • Neurodegenerative Diseases
  • Others

By End-User

  • Hospitals
  • Specialty Clinics
  • Homecare Settings

By Region

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East and Africa

This market research report also emphasis on factors affecting the growth rate in various regions listed above. A deep-down analysis of region will also be provided in the final version of this market which is based on conclusion of primary interviews and secondary data point gathered during the process. 

By region, the market is segmented into North America, Latin America, Europe, Asia-Pacific, and Middle East & Africa. The mature healthcare infrastructure and ongoing research efforts in North America drive significant market presence. The prevalence of chronic conditions like diabetes fuels the demand for AGE diagnostics and treatments, particularly in the United States. In Europe, an aging population and rising cases of diabetes and related complications contribute to a robust AGE market. Countries like Germany and the United Kingdom, with their advanced healthcare systems, serve as crucial market hubs for diagnostics and interventions targeting Ages. The Asia Pacific region showcases a burgeoning market due to rapid urbanization and lifestyle changes, leading to increased diabetes cases. Growing healthcare investments, especially in countries like China and India, create a favourable environment for the uptake of AGEs-related products. Collaborative partnerships between research institutions and pharmaceutical companies further accelerate market growth. Disease burden, healthcare systems, research capabilities, and economic progress shape the AGE market's regional nuances. Adapting strategies to these regional contexts is essential for successful market penetration and growth.

  • Tier 1 players- established companies in the market with a major market share
  • Tier 2 players
  • Emerging players which are growing rapidly
  • New Entrants

  • Growth prospects
  • SWOT analysis
  • Key trends
  • Key data-points affecting market growth

  • To provide with an exhaustive analysis on the of Advanced Glycation End Products Market By Type, By Application, By End-User and By Region.
  • To cater comprehensive insights on factors such as drivers, restraints, trends, opportunity, and additionally segmental and regional factors impacting market growth.
  • To evaluate current market trends and forecast micro-markets and the overall market projections which are represents in format of data-sets and ppt.
  • To predict the market size, in key regions— North America, Europe, Asia Pacific, Latin America and Middle East and Africa. 
  • To provide information on competitors which includes landscape mapping, technological advancements, R&D spending, news concerning strategic alliances, and new product launches

  • We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
  • The customization Mobility Care offered are free of charge with purchase of any license of the report
  • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

 

Table of Contents


  • 1.   Market Introduction
    •   1. Objectives of the Study
        2. Market Definition
        3. Market Scope
         3.1 . Years Considered for the Study
         3.2 . Market Covered
        4. Currency
        5. Limitations
        6. Stakeholders
  • 2.   Research Methodology
    •   1. Research Data
         1.1 . Secondary Data
          1.1.1 . Key Data from Secondary Sources
         1.2 . Primary Data
          1.2.1. Key Data from Primary Sources
        2. Market Size Estimation
        3. Market Breakdown and Data Triangulation
        4. Assumptions for the Study
  • 3.   Executive Summary
    •   1. Market Outlook
        2. Segment Outlook
        3. Competitive Insights
  • 4.   Advanced Glycation End Products Market Variables, Trends & Scope
    •   1. Market Lineage Outlook
        2. Penetration and Growth Prospect Mapping
        3. Industry Value Chain Analysis
        4. Cost Analysis Breakdown
        5. Technology Overview
        6. Regulatory Framework
         6.1. Reimbursement Framework
         6.2. Standards and Compliances

  • 5.   Market Overview
    •   1. Market Dynamics
         1.1. Market Driver Analysis
          1.1.1. Increasing focus of Advanced Glycation End Products Companies on Brand Protection
          1.1.2. Untapped Opportunities in Emerging Regions
         1.2. Market Restraint Analysis
          1.2.1. High Cost Associated with Implementation of Predictive Analysis
         1.3. Industry Challenges
          1.3.1. Presence of Ambiguous Regulatory Framework
  • 6.   Advanced Glycation End Products Market Analysis Tools
    •   1. Industry Analysis - Porter’s
         1.1. Supplier Power
         1.2. Buyer Power
         1.3. Substitution Threat
         1.4. Threat from New Entrants
         1.5. Competitive Rivalry
        2. Pestel Analysis
         2.1. Political Landscape
         2.2. Environmental Landscape
         2.3. Social Landscape
         2.4. Technology Landscape
         2.5. Legal Landscape
        3. Major Deals And Strategic Alliances Analysis
         3.1. Joint Ventures
         3.2. Mergers and Acquisitions
         3.3. Licensing and Partnership
         3.4. Technology Collaborations
         3.5. Strategic Divestments
        4. Market Entry Strategies
        5. Case Studies
  • 7.   Advanced Glycation End Products Market, By Type Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Non-fluorescent AGEs
         1.1. Carboxymethyl-lysine (CML)
         1.2. Carboxyethyl-lysine (CEL)
         1.3. Pyrraline
        2. Fluorescent AGEs
         2.1. Pentosidine
         2.2. Methylglyoxal-lysine dimer (MOLD)

  • 8.   Advanced Glycation End Products Market, By Application Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Diabetic Complications
        2. Cancer
        3. Bone Diseases
        4. Neurodegenerative Diseases
        5. Others

  • 9.   Advanced Glycation End Products Market, By End-User Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Hospitals
        2. Specialty Clinics
        3. Homecare Settings

  • 10.   North America Advanced Glycation End Products Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. U.S.A
         2.2. Canada
         2.3. Mexico
        3. Market Size (USD Million) Forecast for North America 2023-2031

  • 11.   Latin America Advanced Glycation End Products Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Brazil
         2.2. Venezuela
         2.3. Argentina
         2.4. Rest of Latin America
        3. Market Size (USD Million) Forecast for Latin America 2023-2031

  • 12.   Europe Advanced Glycation End Products Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Germany
         2.2. U.K
         2.3. France
         2.4. Italy
         2.5. Spain
         2.6. Russia
         2.7. Poland
         2.8. Rest of Europe
        3. Market Size (USD Million) Forecast for Europe 2023-2031

  • 13.   Asia Pacific Advanced Glycation End Products Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Japan
         2.2. China
         2.3. India
         2.4. Australia and New Zealand
         2.5. ASEAN
         2.6. Rest of Asia Pacific
        3. Market Size (USD Million) Forecast for Asia Pacific 2023-2031

  • 14.   Middle East and Africa Advanced Glycation End Products Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. GCC
         2.2. Israel
         2.3. South Africa
         2.4. Rest of MEA
        3. Market Size (USD Million) Forecast for MEA 2023-2031

  • 15.   Market Share Analysis and Competitive Landscape
    •   1. Global Landscape - Key Players, Revenue and Presence
        2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
        3. Global Emerging Companies
        4. North America - Market Share Analysis and Key Regional Players
        5. Europe - Market Share Analysis and Key Regional Players
        6. Asia Pacific - Market Share Analysis and Key Regional Players
        7. Global Key Player - Growth Matrix
  • 16.   Company Profiles (Competition Dashboard, Competitors Deep Dive, Targeted Antigens Offered and Financial Layouts)
    •   1. Merck KGaA
         1.1. Company Overview
         1.2. Product Portfolio
         1.3. SWOT Analysis
         1.4. Financial Overview
         1.5. Strategic Overview
        2. Diagnoptics Technologies B.V.
         2.1. Company Overview
         2.2. Product Portfolio
         2.3. SWOT Analysis
         2.4. Financial Overview
         2.5. Strategic Overview
        3. Cell Biolabs, Inc.
         3.1. Company Overview
         3.2. Product Portfolio
         3.3. SWOT Analysis
         3.4. Financial Overview
         3.5. Strategic Overview
        4. Shanghai Korain Biotech Co., Ltd.
         4.1. Company Overview
         4.2. Product Portfolio
         4.3. SWOT Analysis
         4.4. Financial Overview
         4.5. Strategic Overview
        5. Scent-Sations, Inc.
         5.1. Company Overview
         5.2. Product Portfolio
         5.3. SWOT Analysis
         5.4. Financial Overview
         5.5. Strategic Overview
        6. Z.I. de la Nau
         6.1. Company Overview
         6.2. Product Portfolio
         6.3. SWOT Analysis
         6.4. Financial Overview
         6.5. Strategic Overview
        7. Koken Co., Ltd.
         7.1. Company Overview
         7.2. Product Portfolio
         7.3. SWOT Analysis
         7.4. Financial Overview
         7.5. Strategic Overview
        8. Rodan & Fields Allergan PlcQ
         8.1. Company Overview
         8.2. Product Portfolio
         8.3. SWOT Analysis
         8.4. Financial Overview
         8.5. Strategic Overview
        9. CHF Solutions
         9.1. Company Overview
         9.2. Product Portfolio
         9.3. SWOT Analysis
         9.4. Financial Overview
         9.5. Strategic Overview
        10. Loreal S.A.
         10.1. Company Overview
         10.2. Product Portfolio
         10.3. SWOT Analysis
         10.4. Financial Overview
         10.5. Strategic Overview
        11. Alma Laser
         11.1. Company Overview
         11.2. Product Portfolio
         11.3. SWOT Analysis
         11.4. Financial Overview
         11.5. Strategic Overview
        12. PhotoMedex Inc.
         12.1. Company Overview
         12.2. Product Portfolio
         12.3. SWOT Analysis
         12.4. Financial Overview
         12.5. Strategic Overview
        13. NuFace
         13.1. Company Overview
         13.2. Product Portfolio
         13.3. SWOT Analysis
         13.4. Financial Overview
         13.5. Strategic Overview
        14. Beiersdorf AG
         14.1. Company Overview
         14.2. Product Portfolio
         14.3. SWOT Analysis
         14.4. Financial Overview
         14.5. Strategic Overview
        15. Takeda
         15.1. Company Overview
         15.2. Product Portfolio
         15.3. SWOT Analysis
         15.4. Financial Overview
         15.5. Strategic Overview
        16. Bayer
         16.1. Company Overview
         16.2. Product Portfolio
         16.3. SWOT Analysis
         16.4. Financial Overview
         16.5. Strategic Overview
        17. Shiseido Company
         17.1. Company Overview
         17.2. Product Portfolio
         17.3. SWOT Analysis
         17.4. Financial Overview
         17.5. Strategic Overview
        18. Ostium Cosmetics
         18.1. Company Overview
         18.2. Product Portfolio
         18.3. SWOT Analysis
         18.4. Financial Overview
         18.5. Strategic Overview
        19. Estee Lauder Companies
         19.1. Company Overview
         19.2. Product Portfolio
         19.3. SWOT Analysis
         19.4. Financial Overview
         19.5. Strategic Overview

  • 17.   Pre and Post COVID-19 Impact
    •   1. Positive influence on the healthcare industry
        2. The financial disruption of the manufacturing sector
        3. Impact of COVID-19 on emerging companies
        4. Significant mandates in the healthcare regulations initiated by administrations
        5. The overall economic slowdown of the developing and developed nations
  • 18.   FutureWise SME Key Takeaway Points for Client
Partner

Our Clients